The findings reach mice, none yet in people. 5 independent labs in 4 countries; 9 trials, 3 with no results posted.
None of its findings points the other way.
Cells and mice: a single group. Worms or flies and humans: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Includes the processes named after it and trials of drugs aimed at it.
5 independent labs in 4 countries
9 trials, 3 with no results posted
Funders: Bundesministerium für Forschung, Technologie und Raumfahrt and others
1 of 5 findings with company ties
9 of 9 trials sponsored by developers of drugs aimed at it
Humans4
Animals46
In silico3
Interventions
1
Bisabolangelone
↓downin mouse cells1
1 study
Bisabolangelone inhibits CSF1R in mouse cells (binding shown by docking, molecular dynamics and CETSA; reversed by CSF1R overexpression).
“Furthermore, Bisabolangelone inhibited osteoclast formation by binding to CSF1R, and overexpression of CSF1R reversed the inhibitory effects of Bisabolangelone on osteoclastogenesis.”
Cellsbinding shown by docking, molecular dynamics and CETSA; reversed by CSF1R overexpression
CSF1R protects against neuron loss in Csf1rΔFIRE/ΔFIRE mice.
“The thalamus is particularly vulnerable to neuropathological changes in the absence of microglia, with atrophy, neuron loss, vascular alterations, macroglial dysregulation, and severe tissue calcification.”
In a 45-day experiment, deoxycholic acid improved bone structure in mice whose ovaries had been removed to model bone loss after menopause.In a 45-day experiment, deoxycholic acid improved bone structure in mice whose ovaries had been removed to model bone loss after menopause.
Higher levels of one spinal-fluid protein were linked to greater dementia risk, with a hazard ratio of 1.325, a measure of relative risk.Higher levels of one spinal-fluid protein were linked to greater dementia risk, with a hazard ratio of 1.325, a measure of relative risk.
Aged male mice showed far larger proteomic shifts than females following microglial removal, including alterations in synaptic and mitochondrial proteins.Aged male mice showed far larger proteomic shifts than females following microglial removal, including alterations in synaptic and mitochondrial proteins.
Mice with amyloid plaques gained more than 2 hours of sleep per day over pretreatment levels, without a change in plaque burden.Mice with amyloid plaques gained more than 2 hours of sleep per day over pretreatment levels, without a change in plaque burden.